Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Feb 8;304(6823):339-43.
doi: 10.1136/bmj.304.6823.339.

Renal protective effect of enalapril in diabetic nephropathy

S Björck  1 , H Mulec, S A Johnsen, G Nordén, M Aurell
Affiliations
Clinical Trial

Renal protective effect of enalapril in diabetic nephropathy

S Björck et al. BMJ. .

Abstract

Objective: To determine whether inhibition of angiotensin converting enzyme can reduce the rate of decline in kidney function more than reducing blood pressure with other antihypertensive treatment.

Design: Prospective, open randomised study lasting a mean of 2.2 years in patients with diabetic nephropathy.

Setting: Three outpatient nephrology clinics.

Patients: 40 patients with insulin dependent diabetes and diabetic nephropathy with reduced renal function.

Intervention: Antihypertensive treatment with enalapril or metoprolol, usually combined with frusemide.

Main outcome measure: Rate of decline in glomerular filtration rate measured as chromium-51 edetic acid clearance.

Results: Glomerular filtration rate declined a mean of 2.0 (SD 3.2) ml/min/year in the group given enalapril and 5.6 (5.9) ml/min/year in the control group. The mean arterial blood pressure during the study was 102 (5) mm Hg in the patients given enalapril and 103 (5) mm Hg in the patients given metoprolol. Urinary albumin excretion during treatment with enalapril was 60% lower than during treatment with metoprolol.

Conclusions: Enalapril has an antiproteinuric effect independent of the effect on systemic blood pressure. Treatment with enalapril can reduce the rate of decline in kidney function in patients with diabetic nephropathy more than equally effective antihypertensive treatment with metoprolol. This points to a specific renal protective effect of angiotensin converting enzyme inhibitors in diabetic nephropathy.

PubMed Disclaimer

Comment in

References

    1. N Engl J Med. 1991 Jan 10;324(2):78-84 - PubMed
    1. Scand J Clin Lab Invest. 1981 Oct;41(6):611-6 - PubMed
    1. Dan Med Bull. 1984 Oct;31(5):349-61 - PubMed
    1. Lancet. 1990 Jun 23;335(8704):1537-8 - PubMed
    1. Kidney Int. 1990 Mar;37(3):880-91 - PubMed

Publication types

LinkOut - more resources